Entry into Five Central and South American Countries

Numeco, a subsidiary of Medytox, announced on August 20 that it has obtained product approval for the botulinum toxin formulation 'Newlux' from Panama’s Drug and Food Administration (DNFD).


With this approval, Numeco has now expanded into five countries in Central and South America, including Peru, Bolivia, the Dominican Republic, and El Salvador.


Botulinum Toxin Newlux. Numeco

Botulinum Toxin Newlux. Numeco

View original image

Numeco plans to continue its partnership with the local distributor that has been leading sales of Medytox's botulinum toxin formulation Meditoxin (exported under the name Neuronox) in the region for over ten years.



A Numeco representative stated, "Central and South America is a market with significant growth in K-aesthetics. By leveraging the global business capabilities and networks that Medytox has accumulated, we will further strengthen the brand presence of the botulinum toxin formulation 'Newlux.'"


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing